In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination.
Significant recent advances in cancer immunotherapeutics include the vaccination of cancer patients with tumor antigen-associated peptide-pulsed dendritic cells (DCs). DC vaccines with homogeneous, mature, and functional activities are required to achieve effective acquired immunity; however, the yield of autologous monocyte-derived DCs varies in each patient. Priming with a low dose of recombinant human granulocyte colony-stimulating factor (rhG-CSF) 16-18 h prior to apheresis resulted in 50% more harvested monocytes, with a significant increase in the ratio of CD11c+CD80+ DCs/apheresed monocytes. The detection of antigen-specific cytotoxic T lymphocytes after Wilms' tumor 1-pulsed DC vaccination was higher in patients treated with rhG-CSF than those who were not, based on immune monitoring using tetramer analysis. Our study is the first to report that DC vaccines for cancer immunotherapy primed with low-dose rhG-CSF are expected to achieve higher acquired immunogenicity.
['Shimodaira|Shigetaka|S|', 'Yanagisawa|Ryu|R|', 'Koya|Terutsugu|T|', 'Hirabayashi|Koichi|K|', 'Higuchi|Yumiko|Y|', 'Sakamoto|Takuya|T|0000-0003-2519-4510', 'Togi|Misa|M|0000-0002-7424-4548', 'Kato|Tomohisa|T|', 'Kobayashi|Takashi|T|', 'Koizumi|Tomonobu|T|', 'Koido|Shigeo|S|0000-0003-0397-4348', 'Sugiyama|Haruo|H|']
granulocyte colony-stimulating factor cancer vaccine vaccination dendritic cell acquired immunity tetramer analysis